AU780711B2 - Novel branched substituted amino derivatives of 3-amino-1-phenyl-H(1,2,4)triazol, methods for producing them and pharmaceutical compositions containing them - Google Patents

Novel branched substituted amino derivatives of 3-amino-1-phenyl-H(1,2,4)triazol, methods for producing them and pharmaceutical compositions containing them Download PDF

Info

Publication number
AU780711B2
AU780711B2 AU25259/01A AU2525901A AU780711B2 AU 780711 B2 AU780711 B2 AU 780711B2 AU 25259/01 A AU25259/01 A AU 25259/01A AU 2525901 A AU2525901 A AU 2525901A AU 780711 B2 AU780711 B2 AU 780711B2
Authority
AU
Australia
Prior art keywords
alkyl
triazol
cyclopropyl
propyl
methylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU25259/01A
Other languages
English (en)
Other versions
AU2525901A (en
Inventor
Michel Geslin
Danielle Gully
Jean-Pierre Maffrand
Pierre Roger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of AU2525901A publication Critical patent/AU2525901A/en
Assigned to SANOFI-AVENTIS reassignment SANOFI-AVENTIS Amend patent request/document other than specification (104) Assignors: SANOFI-SYNTHELABO
Application granted granted Critical
Publication of AU780711B2 publication Critical patent/AU780711B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU25259/01A 1999-12-17 2000-12-14 Novel branched substituted amino derivatives of 3-amino-1-phenyl-H(1,2,4)triazol, methods for producing them and pharmaceutical compositions containing them Ceased AU780711B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9915935A FR2802530B1 (fr) 1999-12-17 1999-12-17 Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
FR99/15935 1999-12-17
PCT/FR2000/003536 WO2001044207A2 (fr) 1999-12-17 2000-12-14 Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2 4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
AU2525901A AU2525901A (en) 2001-06-25
AU780711B2 true AU780711B2 (en) 2005-04-14

Family

ID=9553380

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25259/01A Ceased AU780711B2 (en) 1999-12-17 2000-12-14 Novel branched substituted amino derivatives of 3-amino-1-phenyl-H(1,2,4)triazol, methods for producing them and pharmaceutical compositions containing them

Country Status (33)

Country Link
US (1) US6806282B2 (enExample)
EP (1) EP1242389B1 (enExample)
JP (1) JP4146641B2 (enExample)
KR (1) KR100705525B1 (enExample)
CN (1) CN1293061C (enExample)
AR (1) AR031837A1 (enExample)
AT (1) ATE264847T1 (enExample)
AU (1) AU780711B2 (enExample)
BR (1) BR0017023A (enExample)
CA (1) CA2398772C (enExample)
CO (1) CO5251379A1 (enExample)
CZ (1) CZ302460B6 (enExample)
DE (1) DE60010126T2 (enExample)
DK (1) DK1242389T3 (enExample)
EA (1) EA004957B1 (enExample)
EE (1) EE04778B1 (enExample)
ES (1) ES2219436T3 (enExample)
FR (1) FR2802530B1 (enExample)
HU (1) HUP0204080A3 (enExample)
IL (2) IL150037A0 (enExample)
IS (1) IS2315B (enExample)
ME (1) MEP12108A (enExample)
MX (1) MXPA02006033A (enExample)
NO (1) NO20022828L (enExample)
PL (1) PL203819B1 (enExample)
PT (1) PT1242389E (enExample)
RS (1) RS50289B (enExample)
SK (1) SK285994B6 (enExample)
TR (2) TR200201600T2 (enExample)
TW (1) TWI289554B (enExample)
UA (1) UA73333C2 (enExample)
WO (1) WO2001044207A2 (enExample)
ZA (1) ZA200204422B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455546T1 (de) * 2003-08-06 2010-02-15 Vertex Pharma Aminotriazol-verbindungen als proteinkinase- hemmer
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
JP2011500625A (ja) 2007-10-18 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリ置換された1,2,4−トリアゾール
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
AR070936A1 (es) * 2008-03-19 2010-05-12 Janssen Pharmaceutica Nv 1,2,4 -triazoles trisustituidos
JP5486591B2 (ja) 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
US20130225583A1 (en) * 2010-10-21 2013-08-29 Gerald W. Shipps, Jr. Substituted amino-triazolyl pde10 inhibitors
KR20210064407A (ko) 2014-01-21 2021-06-02 뉴로크린 바이오사이언시즈 인코퍼레이티드 선천성 부신 과형성 치료를 위한 crf1 수용체 길항제
CN104059027B (zh) * 2014-07-01 2015-10-28 河北大学 一类含1,2,4-三唑的(e)-甲氧基亚氨基苯乙酸甲酯类化合物及其制备方法和用途
PL3984523T3 (pl) 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
JP7697933B2 (ja) * 2019-09-25 2025-06-24 オンコアレンディ セラピューティクス エス.エー. 5-(4-((2s,5s)-5-(4-クロロベンジル)-2-メチルモルホリノ)ピペリジン-1-イル)-1h-1,2,4-トリアゾール-3-アミンの製造プロセス
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
ES3039926T3 (en) 2019-12-04 2025-10-27 Neurocrine Biosciences Inc Crf receptor antagonists and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0285893B1 (en) * 1987-03-27 1992-03-18 Kumiai Chemical Industry Co., Ltd. Phenyltriazole derivative and insecticide
US5795905A (en) * 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
FR2763337B1 (fr) * 1997-05-13 1999-08-20 Sanofi Sa Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
FR2802530A1 (fr) 2001-06-22
ES2219436T3 (es) 2004-12-01
NO20022828D0 (no) 2002-06-13
PT1242389E (pt) 2004-08-31
EP1242389A2 (fr) 2002-09-25
KR20020061002A (ko) 2002-07-19
IL150037A0 (en) 2002-12-01
ZA200204422B (en) 2003-11-26
KR100705525B1 (ko) 2007-04-10
EA004957B1 (ru) 2004-10-28
EE04778B1 (et) 2007-02-15
CA2398772C (fr) 2011-07-05
HUP0204080A3 (en) 2005-01-28
HK1055947A1 (en) 2004-01-30
JP4146641B2 (ja) 2008-09-10
RS50289B (sr) 2009-09-08
YU43902A (sh) 2005-03-15
WO2001044207A3 (fr) 2001-12-20
CN1293061C (zh) 2007-01-03
PL203819B1 (pl) 2009-11-30
ATE264847T1 (de) 2004-05-15
JP2003516975A (ja) 2003-05-20
BR0017023A (pt) 2002-12-03
TR200401775T4 (tr) 2004-09-21
WO2001044207A2 (fr) 2001-06-21
CA2398772A1 (fr) 2001-06-21
CZ20022099A3 (cs) 2002-09-11
HUP0204080A2 (hu) 2003-04-28
SK285994B6 (sk) 2008-01-07
DE60010126D1 (de) 2004-05-27
PL355811A1 (en) 2004-05-17
FR2802530B1 (fr) 2002-02-22
EP1242389B1 (fr) 2004-04-21
NO20022828L (no) 2002-08-19
EA200200523A1 (ru) 2002-12-26
DK1242389T3 (da) 2004-08-09
CO5251379A1 (es) 2003-02-28
CN1434808A (zh) 2003-08-06
TR200201600T2 (tr) 2002-10-21
UA73333C2 (en) 2005-07-15
WO2001044207A8 (fr) 2001-07-12
AU2525901A (en) 2001-06-25
IL150037A (en) 2007-02-11
DE60010126T2 (de) 2005-04-28
SK8502002A3 (en) 2003-02-04
WO2001044207B1 (fr) 2002-06-06
MEP12108A (en) 2010-06-10
EE200200331A (et) 2003-06-16
MXPA02006033A (es) 2003-01-28
US6806282B2 (en) 2004-10-19
IS6402A (is) 2002-05-28
CZ302460B6 (cs) 2011-06-01
IS2315B (is) 2007-11-15
AR031837A1 (es) 2003-10-08
US20030162771A1 (en) 2003-08-28
TWI289554B (en) 2007-11-11

Similar Documents

Publication Publication Date Title
US8420679B2 (en) Aminothiazole derivatives and their use as CRF receptor ligands
US6806282B2 (en) Branched substituted amino derivatives of 3-amino-1-phenyl-1h-[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them
IL148313A (en) Derivatives of N - the heterocycles, pharmaceutical preparations containing them and the uses of the said derivatives
JPH06506003A (ja) 新規なイミダゾール誘導体、その製造及びその治療への応用
PL192029B1 (pl) Zastosowanie heterocyklicznych eterów winylowych, nowe heterocykliczne etery winylowe, sposób ich wytwarzania i środek farmaceutyczny
EP0315433A2 (en) 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics
TW200916442A (en) 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1receptor modulators